Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01670110 · ClinicalTrials.gov registry record · Phase 2
Pasireotide LAR in Severe Polycystic Liver Disease
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT01670110: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT01670110 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01670110, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to compare SOM230 treatment to placebo. The investigators will also assess the efficacy and safety of SOM230 in reducing total liver volume and improving quality of life.
Interventions
- DRUG Placebo
- DRUG Pasireotide LAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2012-08 |
| Est. Completion | 2018-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01670110
The ClinicalTrials.gov registry entry for NCT01670110 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01670110 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01670110 about?
NCT01670110 is a clinical study titled "Pasireotide LAR in Severe Polycystic Liver Disease". The purpose of this study is to compare SOM230 treatment to placebo. The investigators will also assess the efficacy and safety of SOM230 in reducing total liver volume and improving quality of life.
What is the current status of trial NCT01670110?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2012-08. Estimated completion is 2018-09.
What interventions are being tested in trial NCT01670110?
The interventions under investigation include: Placebo (DRUG), Pasireotide LAR (DRUG).
Who is sponsoring clinical trial NCT01670110?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.